

IN THE CLAIMS

Please cancel claims 3-8, 12-16, 19, 21-22, 24-25, 28-29, and 40-55, without prejudice or disclaimer.

This listing of the claims replaces all prior versions of the claims in the application.

1. (Original) An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134,
 - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-134,
 - c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, and
 - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.
2. (Original) An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.
- 3-8. (Canceled)
9. (Original) A method of producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - b) recovering the polypeptide so expressed.
10. (Original) A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.
11. (Original) An isolated antibody which specifically binds to a polypeptide of claim 1.
- 12-16. (Canceled)
17. (Original) A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

18. (Original) A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.

19. (Canceled)

20. (Original) A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) contacting a sample comprising a polypeptide of claim 1 with a compound, and
- b) detecting agonist activity in the sample.

21-22. (Canceled)

23. (Original) A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) contacting a sample comprising a polypeptide of claim 1 with a compound, and
- b) detecting antagonist activity in the sample.

24-25. (Canceled)

26. (Original) A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

27. (Original) A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

28-29. (Canceled)

30. (Original) A method for a diagnostic test for a condition or disease associated with the expression of HSPP in a biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. (Original) The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

32. (Original) A composition comprising an antibody of claim 11 and an acceptable excipient.

33. (Original) A method of diagnosing a condition or disease associated with the expression of HSPP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. (Original) A composition of claim 32, further comprising a label.

35. (Original) A method of diagnosing a condition or disease associated with the expression of HSPP in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

36. (Original) A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from the animal, and

- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.

37. (Original) A polyclonal antibody produced by a method of claim 36.

38. (Original) A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. (Original) A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:

- a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-134, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-134.

40-55. (Canceled)